Enzalutamide is active in treating low- and intermediate-risk prostate cancer - Medical Xpress

For patients with low- or intermediate-risk localized prostate cancer, enzalutamide monotherapy plus active surveillance (AS) is well tolerated and induces a significant treatment response compared with AS alone, according to a study published online June 16 …

For patients with low- or intermediate-risk localized prostate cancer, enzalutamide monotherapy plus active surveillance (AS) is well tolerated and induces a significant treatment response compared w… [+2233 chars]

full article...